Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Revenue: 2010-2025

Historic Revenue for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $27.8 million.

  • Anika Therapeutics' Revenue fell 5.89% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.8 million, marking a year-over-year increase of 30.55%. This contributed to the annual value of $119.9 million for FY2024, which is 0.73% down from last year.
  • As of Q3 2025, Anika Therapeutics' Revenue stood at $27.8 million, which was down 1.42% from $28.2 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Revenue ranged from a high of $44.3 million in Q2 2023 and a low of -$2.9 million during Q4 2023.
  • For the 3-year period, Anika Therapeutics' Revenue averaged around $29.4 million, with its median value being $29.6 million (2024).
  • Per our database at Business Quant, Anika Therapeutics' Revenue crashed by 107.78% in 2022 and then skyrocketed by 1,155.61% in 2024.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Revenue stood at $35.8 million in 2021, then plummeted by 107.78% to -$2.8 million in 2022, then declined by 4.02% to -$2.9 million in 2023, then spiked by 1,155.61% to $30.6 million in 2024, then fell by 5.89% to $27.8 million in 2025.
  • Its Revenue was $27.8 million in Q3 2025, compared to $28.2 million in Q2 2025 and $26.2 million in Q1 2025.